Developer docs
API playgroundTry for free, no card

Search company profiles

Pepticom Ltd.

Full company profile

uuid00027hf

Namestring
Pepticom Ltd.
Legal namestring
Pepticom Ltd.
Websiteurl
pepticom.com
Company typeenum
Private
Founded yearint
2015
Descriptiontext

Pepticom Ltd. is a Jerusalem-based artificial intelligence company founded in 2015 that operates a computational platform for the discovery of novel therapeutic peptides. The core technology combines reinforcement learning, first-principles modeling, and generative AI to explore peptide chemical spaces of 10^80 possibilities using 600 natural and non-natural amino acids, with the stated design goal of producing peptide candidates optimized for stability, efficacy, and oral bioavailability within hours. The platform applies peptide-specific chemistries including cyclizations (N-to-C, Disulfide, Thioether, Lasso) and length adjustments of 5-13 amino acids, and integrates preclinical validation data to refine designs.

The business operates two complementary streams: paid discovery collaborations with multinational pharmaceutical and biotech companies, and an in-house pipeline led by an oral IL-17 inhibitor program for plaque psoriasis that the company describes as the world's first AI-designed therapeutic peptide for that indication. The lead asset is in lead optimization with a drug candidate announcement planned for 2025. Pricing is not publicly disclosed; revenue is generated through bespoke collaboration agreements rather than standardized product pricing.

Pepticom maintains research collaborations with Hebrew University of Jerusalem, Oxford University, the Fraunhofer Institute, and Hadassah University Medical Center, and holds a partnership with ADAMA in agricultural applications. In July 2025 it joined Johnson & Johnson's JLABS network as a virtual member across EMEA and Singapore. The company has published five peer-reviewed papers between 2015 and 2022 documenting its reinforcement learning methodology applied to specific therapeutic targets. Total disclosed funding is approximately $14.2 million across three rounds, most recently a $6.6 million Series A1 in January 2025 led by Japan Israel High Tech Ventures 2 LP. Headcount is 11-50 employees.

Short descriptiontext

Pepticom Ltd. is a Jerusalem-based AI company that uses reinforcement learning and generative AI to discover novel therapeutic peptides for pharmaceutical and agricultural partners, while advancing an in-house oral IL-17 inhibitor for plaque psoriasis.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersJerusalem, Israel
HQ citystring
Jerusalem
HQ countrystring
Israel
HQ regionstring
Middle East
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
AI peptide discovery, drug discovery platform, peptide therapeutics, computational chemistry, generative AI drug design
Industry6 codes
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYAFAJAKAG
Amino Acids & Peptides (BCAAs, Collagen Peptides, Bioactive Peptides, L-Theanine)
Agriculture & Food Production/Food Ingredients & Additives/Nutraceutical & Functional Ingredients (Vitamins, Minerals, Omega-3s, Botanicals)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Biological Products, (No Disgnostic Substances)2836
Product category
AI-Driven Drug Discovery Platform
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Drug Discovery Collaborations
TypeProfessional Services
Description

Revenue generation through discovery collaboration deals with large multinational pharmaceutical and biotech companies. The company applies its AI platform to design and discover novel drug candidates for collaborative programs.

pepticom.com
2In-house Drug Development
TypeLicensing Royalties
Description

Advancing proprietary drug pipeline through lead optimization, with plans to announce first drug candidate in 2025 for plaque psoriasis treatment (oral IL-17 inhibitors).

pepticom.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Personnel, Technology or R&D, Operations, Marketing or Sales
GTM typeB2B
B2B
Offering typeSoftware
Software
Core offering1 text field

Pepticom operates an AI-driven peptide drug discovery platform that combines reinforcement learning, first-principles modeling, and generative AI to explore peptide chemical spaces of 10^80 possibilities using 600 natural and non-natural amino acids. The company designs and discovers novel therapeutic peptides for the pharmaceutical and agricultural markets through collaborative discovery agreements with multinational companies and through its own in-house drug development pipeline, including an oral IL-17 inhibitor program for plaque psoriasis.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • World's first AI-designed therapeutic peptide for psoriasis in lead optimization phase
+2 more records
Product overview1 text field

Pepticom offers a single unified AI-driven peptide drug discovery platform that combines reinforcement learning, first-principles modeling, and generative AI technologies. The platform enables rapid exploration of vast peptide chemical spaces (10^80 possibilities) and supports both in-house drug development programs and collaborative discovery projects with external partners. The company's lead in-house program focuses on developing oral IL-17 inhibitors for plaque psoriasis treatment.

Product and service3 records
1AI-driven Peptide Drug Discovery Platform
CategoryAI-Driven Drug Discovery Software
Description

An AI-powered computational platform combining reinforcement learning, first-principles modeling, and generative AI to design and discover novel therapeutic peptides. Explores peptide spaces of 10^80 possibilities using 600 natural and non-natural amino acids to enable discovery of novel therapeutics for previously undruggable targets, unmet medical needs, and oral bioavailability improvement. Used for both in-house drug development and collaborative discovery projects with pharmaceutical and biotech partners.

2Collaborative Peptide Discovery Services
CategoryDrug Discovery Services
Description

Bespoke drug discovery collaboration services in which Pepticom applies its AI platform to design and discover novel peptide drug candidates for partner pharmaceutical and biotech companies. Customers engage through discovery collaboration deals with multinational companies.

3Oral IL-17 Inhibitor Program (Plaque Psoriasis)
CategoryIn-house Drug Development Pipeline
Description

Pepticom's lead in-house drug development program focused on discovering novel oral IL-17 inhibitors for plaque psoriasis treatment, a major unmet medical need. Currently advancing what is believed to be the world's first AI-designed therapeutic peptide for psoriasis, with potential applications extending beyond psoriasis to additional indications.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierMajorTypeStrategic or Co-development PartnerAnnounced on2025-07-01
Description

Pepticom is a virtual member company of Johnson & Johnson's global incubator network JLABS in EMEA and Singapore. JLABS is the largest global network of open innovation ecosystems enabling and empowering emerging companies with knowledge, experience, partnerships, and venture connections across pharmaceutical and medical technology sectors.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic collaboration with Hebrew University of Jerusalem. Co-founder Prof. Anwar Rayan is a researcher at the university. The university contributed to the development of peptide/protein structure prediction and drug discovery algorithms.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Academic collaboration partner. Dr. Shaul Lerner holds PhD and postdoc from the Weizmann Institute. The company has published research with Oxford-affiliated researchers.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research collaboration partner in peptide drug discovery and computational chemistry.

5Hadassah University Medical Center
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Medical research collaboration with Hadassah University Medical Center. Dr. Jonathan Cohen (SAB member) specializes in Cancer Research and Neuroscience at Hadassah.

pepticom.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Collaboration partner. ADAMA is a major multinational crop protection company, indicating cross-industry applications of Pepticom's technology.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

Clinical-stage peptide therapeutics company focused on oral peptide drug discovery and development, with overlapping focus on making peptides orally bioavailable—a core value proposition of Pepticom.

TypeDirect peer
Description

AI-driven small molecule drug discovery company using structure-based deep learning, comparable as an early-stage AI drug discovery platform serving pharma collaborations.

TypeDirect peer
Description

AI and quantum physics-driven drug discovery company offering predictive modeling and CRO services for pharma, comparable in combining computational platform with pharmaceutical partnerships.

TypeDirect peer
Description

AI-driven drug discovery company combining generative AI, reinforcement learning, and multi-modal biology to discover novel therapeutics, directly comparable to Pepticom's AI peptide platform approach.

5Iambic Therapeutics
TypeDirect peer
Description

AI-driven drug discovery company combining physics-based modeling and machine learning to discover novel therapeutics, with comparable scope in AI-first molecular design.

TypeDirect peer
Description

Computational chemistry and AI-driven molecular design platform used for drug discovery across pharma. Comparable as a software-plus-pipeline AI drug discovery company with both platform and proprietary assets.

TypeDirect peer
Description

AI protein engineering company applying generative machine learning to design novel proteins and peptides, directly comparable to Pepticom's AI-driven peptide design capabilities.

TypeDirect peer
Description

AI-driven biotechnology company combining high-throughput biology, machine learning, and generative chemistry to discover novel therapeutics at scale, comparable in mission and AI-first approach.

TypeDirect peer
Description

Generative AI biology company creating novel protein therapeutics, with a similar focus on generative AI for biologic drug design including peptides and protein-based medicines.

10Isomorphic Labs
TypeDirect peer
Description

Alphabet-backed AI drug discovery company applying deep learning to pharmaceutical R&D, including protein structure prediction and small molecule design. Directly comparable as an AI-first drug discovery peer.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI capability5 records

Each record includes

Type, Description, Source

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles15 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds3 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Pepticom Ltd.

AI-Driven Drug Discovery Platformpepticom.com

Pepticom Ltd. is a Jerusalem-based AI company that uses reinforcement learning and generative AI to discover novel therapeutic peptides for pharmaceutical and agricultural partners, while advancing an in-house oral IL-17 inhibitor for plaque psoriasis.

What Pepticom Ltd. does

Pepticom Ltd. is a Jerusalem-based artificial intelligence company founded in 2015 that operates a computational platform for the discovery of novel therapeutic peptides. The core technology combines reinforcement learning, first-principles modeling, and generative AI to explore peptide chemical spaces of 10^80 possibilities using 600 natural and non-natural amino acids, with the stated design goal of producing peptide candidates optimized for stability, efficacy, and oral bioavailability within hours. The platform applies peptide-specific chemistries including cyclizations (N-to-C, Disulfide, Thioether, Lasso) and length adjustments of 5-13 amino acids, and integrates preclinical validation data to refine designs.

The business operates two complementary streams: paid discovery collaborations with multinational pharmaceutical and biotech companies, and an in-house pipeline led by an oral IL-17 inhibitor program for plaque psoriasis that the company describes as the world's first AI-designed therapeutic peptide for that indication. The lead asset is in lead optimization with a drug candidate announcement planned for 2025. Pricing is not publicly disclosed; revenue is generated through bespoke collaboration agreements rather than standardized product pricing.

Pepticom maintains research collaborations with Hebrew University of Jerusalem, Oxford University, the Fraunhofer Institute, and Hadassah University Medical Center, and holds a partnership with ADAMA in agricultural applications. In July 2025 it joined Johnson & Johnson's JLABS network as a virtual member across EMEA and Singapore. The company has published five peer-reviewed papers between 2015 and 2022 documenting its reinforcement learning methodology applied to specific therapeutic targets. Total disclosed funding is approximately $14.2 million across three rounds, most recently a $6.6 million Series A1 in January 2025 led by Japan Israel High Tech Ventures 2 LP. Headcount is 11-50 employees.

Pepticom Ltd. firmographics

Firmographics
Name
Pepticom Ltd.
Legal name
Pepticom Ltd.
Website
https://pepticom.com
Company type
Private
Founded year
2015
Operating status
Operating
Headcount range
11–50 employees
Short description
Pepticom Ltd. is a Jerusalem-based AI company that uses reinforcement learning and generative AI to discover novel therapeutic peptides for pharmaceutical and agricultural partners, while advancing an in-house oral IL-17 inhibitor for plaque psoriasis.
Ownership category
akta.pro rank

Pepticom Ltd. industry classification

Industry
Product category
AI-Driven Drug Discovery Platform
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Biological Products, (No Disgnostic Substances) (2836)
akta.pro industry
PRIMARYHLAGAJAO
AI/ML Platforms for Drug Discovery & Experiment Optimization
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Life Science Software & Informatics (LIMS/ELN/Bioinformatics)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAAAH
Therapeutic Peptides & Protein/Peptide Biologics
Healthcare & Life Sciences/Biotechnology & Biologics/Therapeutic Biologics (mAbs, recombinant proteins, cytokines)
SECONDARYAFAJAKAG
Amino Acids & Peptides (BCAAs, Collagen Peptides, Bioactive Peptides, L-Theanine)
Agriculture & Food Production/Food Ingredients & Additives/Nutraceutical & Functional Ingredients (Vitamins, Minerals, Omega-3s, Botanicals)

Keywords

  • AI peptide discovery
  • Drug discovery platform
  • Peptide therapeutics
  • Computational chemistry
  • Generative AI drug design

Where Pepticom Ltd. is headquartered

Location

Headquarters

HQ city
Jerusalem
HQ country
Israel
HQ region
Middle East

Offices1 record

Markets served

Pepticom Ltd. business model

Business model
GTM type
B2B
Offering type
Software
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales

Revenue model

  1. Drug Discovery Collaborations: Revenue generation through discovery collaboration deals with large multinational pharmaceutical and biotech companies. The company applies its AI platform to design and discover novel drug candidates for collaborative programs.
  2. In-house Drug Development: Advancing proprietary drug pipeline through lead optimization, with plans to announce first drug candidate in 2025 for plaque psoriasis treatment (oral IL-17 inhibitors).

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Pepticom Ltd. product offering

Product offering

Core offering

Pepticom operates an AI-driven peptide drug discovery platform that combines reinforcement learning, first-principles modeling, and generative AI to explore peptide chemical spaces of 10^80 possibilities using 600 natural and non-natural amino acids. The company designs and discovers novel therapeutic peptides for the pharmaceutical and agricultural markets through collaborative discovery agreements with multinational companies and through its own in-house drug development pipeline, including an oral IL-17 inhibitor program for plaque psoriasis.

Product overview

Pepticom offers a single unified AI-driven peptide drug discovery platform that combines reinforcement learning, first-principles modeling, and generative AI technologies. The platform enables rapid exploration of vast peptide chemical spaces (10^80 possibilities) and supports both in-house drug development programs and collaborative discovery projects with external partners. The company's lead in-house program focuses on developing oral IL-17 inhibitors for plaque psoriasis treatment.

Differentiator

Problem solved

Functional benefit

Products and services

  • AI-driven Peptide Drug Discovery Platform An AI-powered computational platform combining reinforcement learning, first-principles modeling, and generative AI to design and discover novel therapeutic peptides. Explores peptide spaces of 10^80 possibilities using 600 natural and non-natural amino acids to enable discovery of novel therapeutics for previously undruggable targets, unmet medical needs, and oral bioavailability improvement. Used for both in-house drug development and collaborative discovery projects with pharmaceutical and biotech partners.
  • Collaborative Peptide Discovery Services Bespoke drug discovery collaboration services in which Pepticom applies its AI platform to design and discover novel peptide drug candidates for partner pharmaceutical and biotech companies. Customers engage through discovery collaboration deals with multinational companies.
  • Oral IL-17 Inhibitor Program (Plaque Psoriasis) Pepticom's lead in-house drug development program focused on discovering novel oral IL-17 inhibitors for plaque psoriasis treatment, a major unmet medical need. Currently advancing what is believed to be the world's first AI-designed therapeutic peptide for psoriasis, with potential applications extending beyond psoriasis to additional indications.

Quantifiable outcome

  • World's first AI-designed therapeutic peptide for psoriasis in lead optimization phase
  • +2 more outcomes

Companies that use Pepticom Ltd.

Customer profile

Segments2 records

Ideal customer profiles2 records

Pepticom Ltd. technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

AI capability5 records

Feature6 records

Pepticom Ltd. partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered major and core.

  • Johnson & Johnson Innovation JLABSmajorStrategic or Co-development Partner · 1 July 2025Pepticom is a virtual member company of Johnson & Johnson's global incubator network JLABS in EMEA and Singapore. JLABS is the largest global network of open innovation ecosystems enabling and empowering emerging companies with knowledge, experience, partnerships, and venture connections across pharmaceutical and medical technology sectors.
  • Hebrew University of JerusalemcoreStrategic or Co-development PartnerAcademic collaboration with Hebrew University of Jerusalem. Co-founder Prof. Anwar Rayan is a researcher at the university. The university contributed to the development of peptide/protein structure prediction and drug discovery algorithms.
  • Oxford UniversitycoreStrategic or Co-development PartnerAcademic collaboration partner. Dr. Shaul Lerner holds PhD and postdoc from the Weizmann Institute. The company has published research with Oxford-affiliated researchers.
  • Fraunhofer InstitutecoreStrategic or Co-development PartnerResearch collaboration partner in peptide drug discovery and computational chemistry.
  • Hadassah University Medical CentercoreStrategic or Co-development PartnerMedical research collaboration with Hadassah University Medical Center. Dr. Jonathan Cohen (SAB member) specializes in Cancer Research and Neuroscience at Hadassah.
  • ADAMAcoreStrategic or Co-development PartnerCollaboration partner. ADAMA is a major multinational crop protection company, indicating cross-industry applications of Pepticom's technology.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Pepticom Ltd. competitors and assessment

Company assessment

Emerging players

  • Crinetics Pharmaceuticals: Clinical-stage peptide therapeutics company focused on oral peptide drug discovery and development, with overlapping focus on making peptides orally bioavailable—a core value proposition of Pepticom.

Direct peers

  • Atomwise: AI-driven small molecule drug discovery company using structure-based deep learning, comparable as an early-stage AI drug discovery platform serving pharma collaborations.
  • XtalPi: AI and quantum physics-driven drug discovery company offering predictive modeling and CRO services for pharma, comparable in combining computational platform with pharmaceutical partnerships.
  • Insilico Medicine: AI-driven drug discovery company combining generative AI, reinforcement learning, and multi-modal biology to discover novel therapeutics, directly comparable to Pepticom's AI peptide platform approach.
  • Iambic Therapeutics: AI-driven drug discovery company combining physics-based modeling and machine learning to discover novel therapeutics, with comparable scope in AI-first molecular design.
  • Schrödinger, Inc. Computational chemistry and AI-driven molecular design platform used for drug discovery across pharma. Comparable as a software-plus-pipeline AI drug discovery company with both platform and proprietary assets.
  • Cradle Bio: AI protein engineering company applying generative machine learning to design novel proteins and peptides, directly comparable to Pepticom's AI-driven peptide design capabilities.
  • Recursion Pharmaceuticals: AI-driven biotechnology company combining high-throughput biology, machine learning, and generative chemistry to discover novel therapeutics at scale, comparable in mission and AI-first approach.
  • Generate Biomedicines: Generative AI biology company creating novel protein therapeutics, with a similar focus on generative AI for biologic drug design including peptides and protein-based medicines.
  • Isomorphic Labs: Alphabet-backed AI drug discovery company applying deep learning to pharmaceutical R&D, including protein structure prediction and small molecule design. Directly comparable as an AI-first drug discovery peer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

Pepticom Ltd. social profiles

Digital presence

Pepticom Ltd. financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Pepticom Ltd. leadership team

Management profile

Number of profiles

Profiles15 records

Pepticom Ltd. funding detail

Funding detail

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Pepticom Ltd. M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pepticom Ltd.

What does Pepticom Ltd. do?

Pepticom operates an AI-driven peptide drug discovery platform that combines reinforcement learning, first-principles modeling, and generative AI to explore peptide chemical spaces of 10^80 possibilities using 600 natural and non-natural amino acids. The company designs and discovers novel therapeutic peptides for the pharmaceutical and agricultural markets through collaborative discovery agreements with multinational companies and through its own in-house drug development pipeline, including an oral IL-17 inhibitor program for plaque psoriasis.

Is Pepticom Ltd. a public or private company?

Pepticom Ltd. is a private company. It is classified as venture growth investor backed and is currently operating.

When was Pepticom Ltd. founded?

Pepticom Ltd. was founded in 2015. It employs 11 to 50 people.

Where is Pepticom Ltd. based?

Pepticom Ltd. is headquartered in Jerusalem, Israel, in the Middle East region.

How does Pepticom Ltd. make money?

Two revenue lines are on record. Drug Discovery Collaborations are the primary driver. The others are in-house Drug Development.

Who are Pepticom Ltd.'s main competitors?

Crinetics Pharmaceuticals is listed as an emerging player. Direct peers are Atomwise, XtalPi, Insilico Medicine, Iambic Therapeutics, Schrödinger, Inc., Cradle Bio, Recursion Pharmaceuticals, Generate Biomedicines and Isomorphic Labs.

Does Pepticom Ltd. have an API?

No public API is recorded for Pepticom Ltd..

What industry is Pepticom Ltd. in?

Pepticom Ltd.'s product category is AI-Driven Drug Discovery Platform. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAAAIAC, Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
HIT ConsultantPepticom Secures $6.6M for AI-Powered Peptide Drug DiscoveryPepticom raised $6.6M in a Series A1 round led by Japan Israel High Tech Ventures LP. The funding will accelerate its oral IL-17 inhibitor program for autoimmune diseases like psoriasis. The company's AI platform designs peptides from over 600 amino acid building blocks.YahooPepticom Announces Successful Completion of Series A1 Funding RoundPepticom completed its Series A1 funding round, raising $6.6 million led by Japan Israel High Tech Ventures 2 LP. The funds will accelerate development of oral IL-17 inhibitors for autoimmune diseases, including two families of synthetic peptidomimetics with nanomolar activity. The company's AI-driven platform explores over 10^80 peptide structures.PR NewswirePepticom Announces Successful Completion of Series A1 Funding RoundPepticom announced completion of its Series A1 funding round, securing $6.6 million led by Japan Israel High Tech Ventures 2 LP. The funds will accelerate development of oral IL-17 inhibitors for autoimmune diseases, including two families of synthetic peptidomimetics with nanomolar activity. The company's AI-driven platform explores over 10^80 peptide structures.NatureBreakthrough technologies transform the discovery and development of peptide drugsPepticom uses AI-driven biocomputational software to design novel peptide drug candidates, including a preclinical psoriasis treatment. The company's platform covers 10^30 chemical solutions and has increased activity of its peptide candidates one thousand-fold. Pepticom is collaborating with pharma and agriculture companies on discovery projects.Tech.euJerusalem-based AI drug design firm Pepticom raises $2.6 million to focus on COVID-19 treatments via PeptiCovPepticom raised $2.6 million from Chartered Group to spin out PeptiCov, focusing on COVID-19 treatments. The company uses AI to screen 1,030 molecular options and has lab-validated peptide drug candidates. No further details on the investment's use were disclosed.PR NewswirePepticom's New Spinout Company, PeptiCov, to Focus on COVID-19Pepticom announced the establishment of a new spinout company, PeptiCov, to focus on developing AI-driven peptide treatments for SARS-CoV-2. The initiative was funded by a $2.6 million investment led by the Chartered Group, which will support the discovery and development of novel peptide molecules targeting the virus.PR NewswireHebrew University Researchers Submit Proposals to Israel Innovation Authority to Investigate Diagnostics, Treatments, and Cures for Covid-19Researchers at The Hebrew University of Jerusalem and several Yissum start-up companies submitted multiple proposals to the Israel Innovation Authority on March 26, 2020, under a fast-track COVID-19 research program. The proposals cover diverse approaches including AI-based drug discovery, antiviral face masks, drug repurposing, and plant-based diagnostic tools, with specific initiatives by Pepticom targeting coronavirus proteins and Enlivex developing treatments for severe COVID-19 symptoms. Yissum, the university's technology transfer company, is actively seeking industry partners to advance these early-stage technologies toward commercialization.FinSMEsPepticom Secures $5M in Series A FundingPepticom, a Jerusalem-based AI drug discovery startup, raised $5M in Series A funding from the Chartered Group. The funds will develop new AI models to improve molecular discovery efficacy and reduce risk. The company, founded in 2011, uses AI to filter peptide-based drug candidates from a chemical space of 10^30 options.GlobesIsraeli AI peptide co Pepticom raises $5mPepticom, an Israeli AI peptide drug discovery company, raised $5 million in a Series A round from Chartered Group. The funding will develop new AI models to improve molecular discovery efficacy and reduce risk. The company claims its technology cuts discovery time by nearly a year.